Regeneron Pharmaceuticals, Inc. (REGN) Financial Statements
Regeneron Pharmaceuticals, Inc. (REGN) reported trailing twelve-month revenue of $15.5B (up 9.3% year on year) and net income of $4.3B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $3.8B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 82.9B
- P/E TTM
- 19.9
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 6 Oct; these figures move once the 10-Q is filed.
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.46 | 0.45 | 1.38 | 2.10 | 2.82 | 4.10 | 4.86 | 5.87 | 5.15 | 6.56 | 8.50 | 16.07 | 12.17 | 13.12 | 14.20 | 14.34 | 15.53 | |
| Gross profit | 0.46 | 0.44 | 1.29 | 1.99 | 2.69 | 3.86 | 4.67 | 5.67 | — | 6.15 | — | — | — | — | — | — | — | |
| Research & development | 0.49 | 0.53 | 0.63 | 0.86 | 1.27 | 1.62 | 2.05 | 2.08 | 1.47 | 2.45 | 2.65 | 2.86 | 3.59 | 4.44 | 5.13 | 5.85 | 6.28 | |
| Operating income | -0.10 | -0.21 | 0.46 | 0.74 | 0.82 | 1.25 | 1.33 | 2.08 | 2.53 | 2.21 | 3.58 | 8.95 | 4.74 | 4.05 | 3.99 | 3.58 | 3.84 | |
| Pre-tax income | -0.10 | -0.22 | 0.41 | 0.70 | 0.76 | 1.23 | 1.33 | 2.08 | 2.55 | 2.43 | 3.81 | 9.33 | 4.86 | 4.20 | 4.78 | 5.23 | 5.17 | |
| Income tax | 0.00 | -0.00 | -0.34 | 0.28 | 0.42 | 0.59 | 0.43 | 0.88 | 0.11 | 0.31 | 0.30 | 1.25 | 0.52 | 0.25 | 0.37 | 0.73 | 0.84 | |
| Net income | -0.10 | -0.22 | 0.75 | 0.41 | 0.34 | 0.64 | 0.90 | 1.20 | 2.44 | 2.12 | 3.51 | 8.08 | 4.34 | 3.95 | 4.41 | 4.50 | 4.33 | |
| Diluted EPS ($) | — | -2.45 | 6.75 | 3.72 | 2.98 | 5.52 | 7.70 | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | 40.47 | |
| Diluted shares (bn) | — | — | 0.115 | 0.111 | 0.113 | 0.115 | 0.116 | 0.116 | 0.115 | 0.115 | 0.115 | 0.112 | 0.114 | 0.114 | 0.115 | 0.109 | — |
USD billions · SEC XBRL
Regeneron Pharmaceuticals, Inc. — questions
- What is Regeneron Pharmaceuticals, Inc.'s revenue?
- $15.5B over the twelve months to 2026-06-30, up 9.3% year on year, from its 10-Q and 10-K filings.
- What is Regeneron Pharmaceuticals, Inc.'s net income?
- $4.3B over the twelve months to 2026-06-30.
- What is Regeneron Pharmaceuticals, Inc.'s free cash flow?
- $3.8B over the twelve months to 2026-06-30.
- What are Regeneron Pharmaceuticals, Inc.'s diluted earnings per share?
- $40.47 over the twelve months to 2026-06-30.
Every figure on this page comes from Regeneron Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.